- NASDAQ: APM ended Tuesday's session with a surge of 90% after hitting even higher levels.
- Shares then collapsed back below $3, completing a pump-and-dump move.
- Aptorum Group launched a new unit focused on an infectious disease liquid biopsy unit.
- Venturing into a new field involving the coronavirus implies strong growth for the low-valued company.
When a stock trades at rock-bottom levels, a small spark is all that is needed to trigger a surge. Aptorum Group Ltd nearly quadrupled in value in Tuesday's intense session, closing at $4.76 after already hitting a high of $14.23. Shares then collapsed back below $3 on a Wednesday session dominated by bears, taking the price back nearly to Monday's levels. On Thursday, trading action was quiet, with NASDAQ:APM closing at $2.89 after staying the whole session between $2.7 and $3.1.
After the recent leap and plunge, NASDAQ: APM's market capitalization is only $87.82 million. Can it rise?
APM Stock News
Aptorum jumped after announcing the launch of Aptorum Innovations, a subsidiary focused on infectious disease liquid biopsy diagnostics. When speaking of diseases that spread rapidly, SARS-Cov-2 – the virus behind COVID-19 – immediately comes to mind.
Indeed, Aptorum has in-licensed exclusive rights to develop novel molecular-based rapid pathogen identification and detection diagnostics (RPIDD) technology with a Singapore-based company called Accelerate Technologies PTE Ltd. The fir is the commercialization arm of the city-state's Agency for Science, Technology, and Research.
The collaboration with a firm backed by Singapore – a country that successfully battled the coronavirus, is inspiring investors.
While several COVID-19 vaccines are at a late stage, there is still room for those specializing in rapid identification of this coronavirus and potentially new ones that could appear in recent years. It is essential to note that the full mitigation of the original SARS disease from 2002-2003 was never fully achieved.
Broader markets are focused on the chaotic presidential debate – which veered away from the virus – yet its prominence is still critical for investors.
See Presidential Debate: Stocks set to suffer on Trump's refusal to accept the results
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
AUD/USD: Next target comes at 0.6550
AUD/USD rebounded sharply on Monday, quickly setting aside the initial drop below the 0.6400 support and revisiting the 0.6470 region on the back of potential extra stimulus in China and ahead of the key RBA’s interest rate decision on Tuesday.
EUR/USD remains under pressure well below 1.0600
EUR/USD failed to test or surpass the key 1.0600 barrier and eventually succumbed to the late bounce in the US Dollar against the backdrop of steady expectations prior to the release of US CPI data on Wednesday.
Gold holds on to gains above $2,660
Gold gathers bullish momentum and trades above $2,670 on Monday. News of China planning to inject further stimulus into the economy boosts XAU/USD as investors gear up for this week's key data releases and central bank meetings.
How high Solana can rally in December, and can SOL beat XRP?
Solana (SOL) is currently consolidating after hitting its all-time high at $264.39 on November 22. While SOL is consolidating, trade volume declined, however, total open interest remains above average levels.
Bitcoin Price Forecast: Amazon shareholders advocate for BTC adoption amid Microsoft’s investment vote
Bitcoin edges down 2.5%, trading below $98,500 on Monday, after rallying 4% and reaching a new all-time high of $104,088 last week. As BTC reached its $100K milestone, big corporates showed interest in the largest digital asset by market capitalization.
Best Forex Brokers with Low Spreads
VERIFIED Low spreads are crucial for reducing trading costs. Explore top Forex brokers offering competitive spreads and high leverage. Compare options for EUR/USD, GBP/USD, USD/JPY, and Gold.